Table 2.

Baseline characteristics of patients with combined end point, complete remission alone, or no remission; patients with or without relapse after initial remission; and responders or nonresponders

CharacteristicCombined End Point
(n=84)Complete Remission
(n=43)No Remission
(n=48)Relapse
(n=25)No Relapse
(n=59)Responders
(n=18)Nonresponders
(n=16)
Age (y)55.0±16.355.7±16.857.0±13.951.3±15.256.6±16.659.6±16.954.0±12.9
Male sex, n (%)54 (64.3)a24 (55.8)a46 (95.8)17 (68.0)37 (62.7)11 (61.1)15 (93.8)e
Previous duration of proteinuria (mo)25.2(10.8–68.6)21.1 (9.3–64.2)34.3 (11.5–75.8)25.2 (11.9–64.5)25.3 (10.7–68.6)15.7 (8.8–27.5)18.8 (11.2–50.4)
Previous immunosuppression, n (%)27 (32.1)14 (32.6)22 (45.8)8 (32.0)19 (32.2)4 (22.2)6 (37.5)
B cell–driven protocol, n (%)60 (71.4)b30 (69.8)b42 (87.5)15 (60.0)45 (76.3)13 (72.2)15 (93.8)
Clinical parameters
 Body weight (kg)75.3±13.673.5±15.678.2±12.275.3±10.475.3±14.875.6±14.880.9±13.0
 Systolic BP (mmHg)133.4±17.9131.2±14.6135.8±17.9128.4±16.6135.7±18.1138.1±15.0132.1±15.1
 Diastolic BP (mmHg)81.6±9.679.3±8.383.0±11.081.3±11.781.8±8.680.5±7.783.1±11.1
Laboratory parameters
 Serum creatinine (mg/dl)1.10 (0.97–1.57)a1.09 (0.90–1.21)a1.65 (1.11–2.26)1.03 (0.95–1.41)1.14 (0.97–1.58)1.12 (0.91–1.29)1.40 (1.13–1.94)e
 Serum albumin (g/dl)2.31±0.61b2.41±0.55c2.06±0.502.30±0.622.31±0.622.19±0.572.03±0.49
 Total cholesterol (mg/dl)241 (208–311)b233 (208–294)b288 (235–354)280 (212–318)235 (208–303)270 (216–311)272 (215–320)
 HDL cholesterol (mg/dl)51 (42–65)55 (50–72)c47 (39–60)59 (49–73)50 (42–63)58 (50–64)47 (41–60)
 Triglycerides (mg/dl)134 (100–182)a115 (87–166.5)a246.5 (189–302.5)147 (113–198)131 (95–177)105 (80–177)270 (110–347)e
 Proteinuria (g/24h)7.6 (4.9–10.8)a6.3(3.8–9.3)a12.5 (9.0–14.8)7.5 (4.9–10.6)7.8 (5.5–10.8)7.6 (5.6–10.5)12.9 (10.9–14.8)f
Anti-PLA2R antibody
 Undetectable, n (%)12 (14.3)7 (16.3)8(16.7)3 (12.0)9 (15.3)NANA
 Detectable, n (%)48 (51.1)28 (65.1)33 (68.7)14 (56.0)34 (57.6)18 (100)16 (100)
 Not available, n (%)24 (28.6)8 (18.6)7 (14.6)8 (32.0)16 (27.1)NANA
 Titer (RU/ml)101.2 (46.6-181.9)c86.7(36.5-145.7)a 212.9 (116.5-352.6)65.2 (45.8-152.4)103.0 (47.4-186.5)101.2 (45.3-139.1)351.3 (192.7-429.0)d
Re-emergence after depletion, n (%)10/44 (22.7)8/26 (30.8)NA8/13 (61.5)2/31 (6.5)d NANA
Increase after reduction, n (%)13/44 (29.6)9/26 (34.6)NA10/13 (76.9)3/31 (9.7)d NANA
  • Variables expressed as mean±SD are compared using one-way ANOVA; variables expressed as median and IQR are compared using Kruskal–Wallis test. Categorical variables are expressed in percentage and compared using Pearson chi-squared test or Fisher exact test, as appropriate. NA, not applicable; Nonresponders, patients with persistent nephrotic syndrome without autoantibody depletion; Responders, patients with persistent remission and anti-PLA2R autoantibody depletion.

  • a P<0.001 for combined end point or complete remission versus no remission.

  • b P<0.05 for combined end point or complete remission versus no remission.

  • c P<0.01 for combined end point or complete remission versus no remission.

  • d P<0.001 for no relapse versus relapse or nonresponders versus responders.

  • e P<0.05 for no relapse versus relapse or nonresponders versus responders.

  • f P<0.01 for no relapse versus relapse or nonresponders versus responders.